Adjuvants for foot-and-mouth disease virus vaccines: recent progress

Reference

• Parida S. Vaccination against foot-and-mouth disease virus: strategies and effectiveness. Expert Rev Vaccines 2009;3:347-65
   Google Scholar
• Shao JJ, Wong CK, Lin T, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin Vaccine Immunol 2011;18:143-9
   PubMed Web of Science ®Google Scholar
• Cao YM, Lu ZJ, Li YL, et al. Poly (I: C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs. Antiviral Res 2013;97:145-53
   PubMed Web of Science ®Google Scholar
• Guo HC, Sun SQ, Jin Y, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res 2013;44:48
   PubMed Web of Science ®Google Scholar
• Porta C, Kotecha A, Burman A, et al. Rational Engineering of Recombinant Picornavirus Capsids to Produce Safe, Protective Vaccine Antigen. PLoS Pathog 2013;9(3):e1003255
   PubMed Web of Science ®Google Scholar
• Uddowla S, Hollister J, Pacheco JM, et al. A safe foot-and-mouth disease vaccine platform with two negative markers for differentiating infected from vaccinated animals. J Virol 2012;86:11675-85
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007;25:3752-62
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503
   PubMed Web of Science ®Google Scholar
• Barnett PV, Pullen L, Williams L, et al. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine 1996;14:1187-98
   PubMedGoogle Scholar
• Patil PK, Bayry J, Ramakrishna C, et al. Immune responses of goats against foot-and-mouth disease quadrivalent vaccine: comparison of double oil emulsion and aluminium hydroxide gel vaccines in eliciting immunity. Vaccine 2002;20:2781-9
   PubMedGoogle Scholar
• Barnett PV, Carabin H. A review of emergency foot-and-mouth disease (FMD) vaccines. Vaccine 2002;20:1505-14
   PubMed Web of Science ®Google Scholar
• Dar P, Kalaivanan R, Sied N, et al. Montanide ISA™201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle. Vaccine 2013;31:3327-32
   PubMed Web of Science ®Google Scholar
• Li D, Zhou CX, She DL, et al. The comparison of the efficacy of swine FMD vaccine emulsified with oil adjuvant of ISA 201 VG or ISA 206 VG. J Biosci Med 2013;1:22-5
   Google Scholar
• Cao Y, Lu Z, Li D, et al. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease in pigsvaccinated with multi-epitope protein vaccine incorporated with poly(I:C). Vet Microbiol 2014;168:294-301
   PubMed Web of Science ®Google Scholar
• Li P, Lu Z, Bai X, et al. Evaluation of a 3A-truncated foot-and-mouth disease virus in pigs for its potential as a marker vaccine. Vet Res 2014;45:51
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000;19:1180-7
   PubMed Web of Science ®Google Scholar
• Sambhara S, Kurichh A, Miranda R, et al. Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses. Cell Immunol 2001;210:1-4
   PubMedGoogle Scholar
• Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30:23-32
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Schnurr M, Wilson NS, et al. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009;87:371-6
   PubMedGoogle Scholar
• Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101:10697-702
   PubMed Web of Science ®Google Scholar
• Xiao C, Rajput ZI, Hu S. Improvement of a commercial foot-and-mouth disease vaccine by supplement of Quil A. Vaccine 2007;25:4795-800
   PubMed Web of Science ®Google Scholar
• Bayry J, Prabhudas K, Gopalakrishna S, et al. Protective immune response to 16 kDa immunoreactive recombinant protein encoding the C-terminal VP1 portion of Foot and Mouth Disease Virus type Asia 1. Microbiol Immunol 1999;43:765-71
   PubMedGoogle Scholar
• Gao FS, Feng L, Zhang Q, et al. Immunogenicity of two FMDV. nonameric peptides encapsulated in liposomes in mice and the protective efficacy in guinea pigs. PLoS One 2013;8:e68658
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-50
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006;22:561-9
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-5
   PubMed Web of Science ®Google Scholar
• Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009;206:1589-602
   PubMed Web of Science ®Google Scholar
• Wang Y, Cella M, Gilfillan S, et al. Cutting edge: polyinosinic: polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 2010;184:2751-5
   PubMed Web of Science ®Google Scholar
• McCartney S, Vermi W, Gilfillan S, et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009;206:2967-76
   PubMed Web of Science ®Google Scholar
• Zhang LL, Bai J, Liu J, et al. Toll-like receptor ligands enhance the protective effects of vaccination against porcine reproductive and respiratory syndrome virus in swine. Vet Microbiol 2013;164:253-60
   PubMedGoogle Scholar
• Houston WE, Crabbs CL, Stephen EL, et al. Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun 1976;14:318-19
   PubMed Web of Science ®Google Scholar
• Knight DJ, Leiper JW, Gough RE, et al. Continued studies on the adjuvancy effect of natural and synthetic double-stranded RNA preparations with inactivated Newcastle disease vaccines in fowls. Res Vet Sci 1977;23:38-42
   PubMedGoogle Scholar
• Derbyshire JB, Lesnick CE. The effect of interferon induction in newborn piglets on the humoral immune response to oral vaccination with transmissible gastroenteritis virus. Vet Immunol Immunopathol 1990;24:227-34
   PubMedGoogle Scholar
• Cunliffe HR, Richmond JY, Campbell CH, et al. Interferon inducers and foot-and-mouth disease vaccines: influence of two synthetic polynucleotides on antibody response and immunity in guinea pigs and swine. Can J Comp Med 1977;41:117-21
   PubMedGoogle Scholar
• Maes RF, Vieira A, Gomes I, et al. Potentiation of FMD vaccines with polycationic-nucleic acid complexes. Arch Virol 1977;55:275-85
   PubMedGoogle Scholar
• Cao YM, Lu ZJ, Li PH, et al. Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant. J Virol Methods 2012;185:124-8
   PubMedGoogle Scholar
• Stahl-Hennig C, Eisenblatter M, Jasny E, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009;5:e1000373
   PubMed Web of Science ®Google Scholar
• Dias CC, Moraes MP, Weiss M, et al. Novel antiviral therapeutics to control foot-and-mouth disease. J Interferon Cytokine Res 2012;32:462-73
   PubMedGoogle Scholar
• Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595-602
   PubMed Web of Science ®Google Scholar
• Harandi AM, Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 2004;5:141-5
   PubMedGoogle Scholar
• Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10:499-511
   PubMed Web of Science ®Google Scholar
• Mapletoft JW, Oumouna M, Townsend HG, et al. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 2006;353:316-23
   PubMedGoogle Scholar
• Linghua Z, Xingshan T, Fengzhen Z. Vaccination with porcine reproductive and respiratory syndrome killed virus vaccine and immunostimulatory oligodeoxynucleotides induces specific immunity in piglets. Vaccine 2007;25:1735-42
   PubMedGoogle Scholar
• Linghua Z, Xingshan T, Fengzhen Z. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets. Vaccine 2008;26:224-33
   PubMedGoogle Scholar
• Sagara I, Ellis RD, Dicko A, et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 2009;27:7292-8
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136-43
   PubMed Web of Science ®Google Scholar
• Ren JL, Yang L, Xu HF, et al. CpG oligodeoxy- nucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle. Vaccine 2011;29:7960-5
   PubMed Web of Science ®Google Scholar
• Kamstrup S, Frimann TH, Barfoed AM. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Antiviral Res 2006;72:42-8
   PubMedGoogle Scholar
• Clves MP, Guzylack-Piriou L, Juillard V, et al. Innate Immune Defenses Induced by CpG Do Not Promote Vaccine-Induced Protection against Foot-and-Mouth Disease Virus in Pigs. Clin Vaccine Immunol 2009;16:1151-7
   PubMedGoogle Scholar
• Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200
   PubMed Web of Science ®Google Scholar
• Gribar SC, Anand RJ, Sodhi CP, et al. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 2008;83:493-8
   PubMed Web of Science ®Google Scholar
• Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3 M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 2007;56:1133-41
   PubMed Web of Science ®Google Scholar
• Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9
   PubMed Web of Science ®Google Scholar
• Zhang WW, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 2008;76:3777-83
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005;102:15190-4
   PubMed Web of Science ®Google Scholar
• Velasquez LS, Hjelm BE, Arntzen CJ, et al. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 2010;17:1850-8
   PubMed Web of Science ®Google Scholar
• Zhou CX, Li D, Chen YL, et al. Resiquimod and polyinosinic–polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine. BMC Vet Res 2014;10:2
   PubMedGoogle Scholar
• Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-103
   PubMed Web of Science ®Google Scholar
• Hong SH, Byun YH, Nguyen CT, et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 2012;30:466-74
   PubMed Web of Science ®Google Scholar
• Vassilieva EV, Wang BZ, Vzorov AN, et al. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio 2011;2:e00328-10
   PubMedGoogle Scholar
• Honko AN, Sriranganathan N, Lees CJ, et al. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006;74:1113-20
   PubMed Web of Science ®Google Scholar
• Hajam IA, Dar PA, Chandrasekar S, et al. Co-administration of flagellin augments immune responses to inactivated foot-and-mouth disease virus (FMDV) antigen. Res Vet Sci 2013;95:936-41
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Jacobs AR, Tang J, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007;25:763-75
   PubMed Web of Science ®Google Scholar
• McCullough KC, Pullen L, Parkinson D. The immune response against foot-and-mouth disease virus: influence of the T lymphocyte growth factors IL-1 and IL-2 on the murine humoral response in vivo. Immunol Lett 1992;1:41-6
   Google Scholar
• Yadav S, Sharma R, Chhabra R. Interleukin-2 potentiates foot-and-mouth disease vaccinal immune responses in mice. Vaccine 2005;23:3005-9
   PubMed Web of Science ®Google Scholar
• Cheng G, Zhao X, Yan W, et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 2007;25:5199-208
   PubMed Web of Science ®Google Scholar
• Du Y, Li Y, He H, et al. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine. J Virol Methods 2008;149:144-52
   PubMedGoogle Scholar
• Li Y, Aggarwal N, Takamatsu H, et al. Enhancing immune responses against a plasmidDNAvaccine encoding a FMDV empty capsid from serotype O. Vaccine 2006;24:4602-6
   PubMed Web of Science ®Google Scholar
• Cedillo-Barron L, Foster-Cuevas M, Belsham GJ, et al. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol 2001;82:1713-24
   PubMed Web of Science ®Google Scholar
• Ma M, Jin N, Shen G, et al. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18. Vet Immunol Immunopathol 2008;121:1-7
   PubMed Web of Science ®Google Scholar
• Ma MX, Jin NY, Liu HJ, et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18. Antiviral Res 2007;76:59-67
   PubMedGoogle Scholar
• de Avila Botton S, Brum MC, Bautista E, et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006;24:3446-56
   PubMed Web of Science ®Google Scholar
• Holmgren J, Adamsson J, Anjuère F, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005;97:181-8
   PubMed Web of Science ®Google Scholar
• Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis 2000;31:561-5
   PubMedGoogle Scholar
• Song HH, Wang ZL, Zheng DX, et al. A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine. Biotechnol Lett 2005;27:1669-74
   PubMed Web of Science ®Google Scholar
• Hu B, Li C, Lu HJ, et al. Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit. J Virol Methods 2011;171:272-9
   PubMed Web of Science ®Google Scholar
• Tempesta M, Camero M, Bellacicco AL, et al. Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats. Vaccine 2007;25:7927-30
   PubMedGoogle Scholar
• Romero JF, Ciabattini A, Guillaume P, et al. Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge. Vaccine 2009;27:1266-71
   PubMed Web of Science ®Google Scholar
• Kende M, Tan X, Wlazlowski C, et al. Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72. Vaccine 2007;25:3219-27
   PubMed Web of Science ®Google Scholar
• Alejo DM, Moraes MP, Liao XF, et al. An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. Vaccine 2013;31:2302-9
   PubMedGoogle Scholar